Relative bioavailability of oral suspension of rivaroxaban compared to standard tablet

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-001720-19

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective of the study is to characterize the pharmacokinetics of 10 and 20 mg of rivaroxaban administered as an oral suspension in comparison to a 10 mg immediate release tablet. The potential for a food effect will be investigated for the 20 mg oral suspension


Critère d'inclusion

  • healthy volunteers (Prevention and teatment of thromboembolic disorders)

Liens